VEGFA and Miyoshi myopathy: Another clinical trial (NCT01183663) involving anti-VEGF monoclonal antibody (bevacizumab) was aimed at defining the highest tolerable doses of the safe combination of drugs effective in advanced cancer treatment [115]; nevertheless, no significant result has been achieved for MM patients [116].